BeOne Medicines Wins FDA Approval for BEQALZI in Mantle Cell Lymphoma
SAN CARLOS, Calif., May 13, 2026 BeOne Medicines announced that the U.S. Food and Drug Administration (FDA) has granted...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Bispecific Antibody cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech medtech innovation Monoclonal Antibody Neurodegenerative Disease Oncology oncology innovation Ophthalmology Orphan Drug orphan drug designation Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
SAN CARLOS, Calif., May 13, 2026 BeOne Medicines announced that the U.S. Food and Drug Administration (FDA) has granted...
LUND, Sweden – May 12, 2026 BioInvent International AB announced that new clinical findings from its ongoing Phase 1/2...
SEATTLE, May 12, 2026 Sana Biotechnology announced new preclinical findings at the 2026 American Society of Gene & Cell...
